Database Query Results : nicotinamide adenine dinucleotide, ,

NAD, nicotinamide adenine dinucleotide: Click to Expand ⟱
Features:
(Nicotinamide adenine dinucleotide) is a vital coenzyme found in all living cells.
• It exists in two forms: oxidized (NAD⁺) and reduced (NADH), playing central roles in redox reactions, energy metabolism, and various signaling pathways.
• NAD⁺ is essential for critical cellular processes, including ATP production, DNA repair (via enzymes like PARPs), and regulation of sirtuins (a family of NAD⁺-dependent deacetylases involved in cellular stress responses and longevity).

NAD⁺ is integral to energy metabolism, redox balance, DNA repair, and cellular regulatory functions—processes that are often dysregulated in cancer.

Medicor Cancer Centres offers it:

-involved in glycolysis, the tricarboxylic acid (TCA) cycle, and oxidative phosphorylation.
-NMN is a precursor to nicotinamide adenine dinucleotide (NAD+)
-alternative form of vitamin B, amide of nicotinic acid
-NAD+ levels decline as we age
-high dose NMN promotes ferroptosis through NAM-mediated SIRT1-AMPK-ACC signaling
-At low doses (10 and 20 mM) and prolonged exposure (48 h), NMN increased cell proliferation, but it induced the suppression of cell proliferation at the high dose (100 mM)
-VitB3 and niacin are precursors for the synthesis of NAD in the body

NAD in Cancer Is Dual-Edge
Tumors need NAD+ to sustain:
-Glycolysis (Warburg)
-PARP DNA repair
-Sirtuin survival signaling
-Redox buffering
NAD depletion (via NAMPT inhibition or high PARP consumption) can:
-Collapse ATP
-Increase ROS
-Trigger apoptosis

Rank Pathway / Axis Cancer / Tumor Context Normal Tissue Context TSF Primary Effect Notes / Interpretation
1 NAD+ salvage pathway (NAMPT → NMN → NAD+) NAD+ pool ↑ supports glycolysis, DNA repair, PARP activity; NAMPT often upregulated Maintains metabolic homeostasis R, G Metabolic support node Many tumors depend on NAMPT-driven NAD+ salvage; NAMPT inhibitors (e.g., FK866) deplete NAD+ and induce energetic collapse.
2 Glycolysis support (LDH-dependent NAD+ recycling) NAD+ regeneration sustains Warburg flux Normal glycolytic tissues also require NAD+ P, R Warburg sustainment LDH converts NADH → NAD+ to maintain glycolytic flux; NAD+ availability is a rate-limiting factor in high glycolysis tumors.
3 PARP-mediated DNA repair (NAD+ consumption) DNA damage repair ↑; therapy resistance ↑ (context) Genome stability maintenance R, G DNA repair capacity PARPs consume NAD+ during DNA repair. PARP inhibitors exploit tumors with HR defects (e.g., BRCA).
4 Sirtuin signaling (SIRT1–7; NAD+-dependent deacetylases) Context-dependent tumor survival or suppression Metabolic regulation, longevity pathways R, G Epigenetic/metabolic modulation Sirtuins require NAD+; effects vary by tumor type (pro-survival in some, suppressive in others).
5 Redox balance (NAD+/NADH ratio) High NAD+/NADH ratio supports anabolic growth Redox homeostasis P, R Redox control Altered NAD+/NADH ratios influence ROS, mitochondrial function, and metabolic flexibility.
6 CD38/CD157 NAD+ degradation NAD+ depletion influences immune and tumor metabolism Immune modulation, aging R, G Immune-metabolic interface CD38 overexpression can lower NAD+ pools; relevant in immune microenvironment contexts.
7 OXPHOS support (mitochondrial NADH supply) NADH fuels ETC; supports mitochondrial ATP production Normal energy metabolism P, R Mitochondrial respiration support NADH oxidation via Complex I regenerates NAD+; OXPHOS-dependent tumors rely on this axis.
8 Therapy resistance modulation NAD+ restoration may reduce oxidative therapy efficacy May protect normal tissue from oxidative injury G Context-dependent NAD+ boosting (e.g., NR, NMN) may theoretically support tumor repair pathways; data mixed and context-specific.
9 NAMPT inhibition (therapeutic strategy) NAD+ depletion → ATP ↓ → apoptosis ↑ Toxicity risk in high-turnover tissues R, G Metabolic collapse NAMPT inhibitors are being explored as anti-cancer metabolic therapies.
10 Bioavailability / supplementation constraint Systemic NAD+ boosting may not selectively target tumor NAD pools Systemic NAD+ supports normal tissue repair — Translation constraint Oral precursors (NR, NMN, niacin) increase systemic NAD+ but tumor-specific impact remains unclear.

TSF: P = 0–30 min (redox flux shifts), R = 30 min–3 hr (metabolic signaling changes), G = >3 hr (gene-level adaptation, repair, phenotype changes).



Scientific Papers found: Click to Expand⟱
2931- NAD,    NAD+ Repletion Rescues Female Fertility during Reproductive Aging
- in-vivo, Nor, NA
*eff↑, *SIRT2↑, *other↑, *Dose↝,
2932- NAD,    Neuroprotective effects and mechanisms of action of nicotinamide mononucleotide (NMN) in a photoreceptor degenerative model of retinal detachment
- in-vitro, Nor, NA
*SIRT1↑, *HO-1↑, *neuroP↑, *Apoptosis↓, *Inflam↓, *ROS↓, *antiOx↑, *toxicity↓,
2933- NAD,    Nicotinamide mononucleotide (NMN) as an anti-aging health product – Promises and safety concerns
- Review, Nor, NA - NA, AD, NA - NA, Diabetic, NA - NA, Stroke, NA - NA, LiverDam, NA - NA, Park, NA
*mtDam↓, *BioAv↝, *BioAv↑, *OS↑, *eff↑, *eff↑, *cognitive↑, *DNAdam↓, *SIRT1↑, *cardioP↑, *ROS↓, *Dose↝, *BioAv↑, *hepatoP↑, *eff↑, *BG↓, *creat↓,
2934- NAD,    The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial
- Trial, Nor, NA
*Dose↑, *Strength↑,
2935- NAD,    Long-term NMN treatment increases lifespan and healthspan in mice in a sex dependent manner
- in-vitro, Nor, NA
*GutMicro↑, *OS↑,
2936- NAD,    The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update
*ROS↓, *DNAdam↓, *neuroP↑, *Inflam↓, *BioAv↑, *SIRT1↑, BioAv↝,
2937- NAD,    High-Dosage NMN Promotes Ferroptosis to Suppress Lung Adenocarcinoma Growth through the NAM-Mediated SIRT1-AMPK-ACC Pathway
- in-vitro, Lung, A549
SIRT1↑, Dose↝, TumCP⇅, Ferroptosis↑, lipid-P↑, AMPK↑, ACC↑,
2938- NAD,    NAD+ supplementation limits triple-negative breast cancer metastasis via SIRT1-P66Shc signaling
- in-vivo, BC, NA
TumMeta↓, SIRT1↑,
2939- NAD,  Rad,    NMN ameliorated radiation induced damage in NRF2-deficient cell and mice via regulating SIRT6 and SIRT7
- in-vitro, Nor, NA
*SIRT6↑, *DNAdam↓, *radioP↑, *ROS↓,
4035- NAD,  VitB3,    NAD+ supplementation reduces neuroinflammation and cell senescence in a transgenic mouse model of Alzheimer's disease via cGAS-STING
- in-vitro, AD, NA
*Inflam↓, *DNAdam↓, *NLRP3↓, *cGAS–STING↓,
4036- NAD,  VitB3,    NAD+ supplementation normalizes key Alzheimer’s features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency
- in-vivo, AD, NA
*Inflam↓, *p‑tau↓, *DNAdam↓, *memory↑, *motorD↑, *cognitive↑, *BBB↑, IL1β↓, *TNF-α↓, *MCP1↓, *RANTES↓, *ROS↓, *SIRT3↑, *SIRT6↑,
4160- NAD,    The biochemical pathways of central nervous system neural degeneration in niacin deficiency
- Review, NA, NA
*BDNF↑, *TrkB↑,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 12

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   HO-1↑, 1,   ROS↓, 5,   SIRT3↑, 1,  

Mitochondria & Bioenergetics ⓘ

mtDam↓, 1,  

Core Metabolism/Glycolysis ⓘ

SIRT1↑, 3,   SIRT2↑, 1,  

Cell Death ⓘ

Apoptosis↓, 1,  

Transcription & Epigenetics ⓘ

other↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↓, 5,   SIRT6↑, 2,  

Barriers & Transport ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling ⓘ

Inflam↓, 4,   MCP1↓, 1,   RANTES↓, 1,   TNF-α↓, 1,  

Cellular Microenvironment ⓘ

cGAS–STING↓, 1,  

Synaptic & Neurotransmission ⓘ

BDNF↑, 1,   p‑tau↓, 1,   TrkB↑, 1,  

Protein Aggregation ⓘ

NLRP3↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 3,   BioAv↝, 1,   Dose↑, 1,   Dose↝, 2,   eff↑, 4,  

Clinical Biomarkers ⓘ

BG↓, 1,   creat↓, 1,   GutMicro↑, 1,  

Functional Outcomes ⓘ

cardioP↑, 1,   cognitive↑, 2,   hepatoP↑, 1,   memory↑, 1,   motorD↑, 1,   neuroP↑, 2,   OS↑, 2,   radioP↑, 1,   Strength↑, 1,   toxicity↓, 1,  
Total Targets: 39

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:268  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page